Abstract
Background
Drugs should be made available to all patients in a timely manner regardless of whether they are adults or children. In contrast to the United States (US) and the European Union (EU), no laws mandating pediatric drug development have been established in Japan. The objective of this study was to examine the current status and characteristics of pediatric drug development in Japan using information on the approval lag for pediatric indications between Japan and the EU.
Methods
Drugs approved for pediatric indications between January 2007 and December 2018 in Japan were studied. The approval lag for pediatric indications between Japan and the EU was calculated and analyzed by approval time and the Anatomical Therapeutic Chemical (ATC) classification. Factors potentially affecting the approval lag, such as orphan drug status, company nationality, and clinical data package, were examined.
Results
The median approval lag for 105 drugs with pediatric indications in both Japan and the EU was 1017 days (Japan was behind). The lag for ATC category B improved significantly after 2011, and for category L after 2015; the medians were less than half a year. The lag for drugs developed globally via multi-regional clinical trials was significantly shorter compared with drugs developed regionally.
Conclusion
Global clinical trials are the most effective means of shortening approval lag time in pediatric drug development. Global development is making rapid progress for many adult diseases, thereby creating an environment for proactive participation in global clinical trials even for pediatric drugs. For further improvement, more active drug development for pediatric indication is recommended in tandem with the US and the EU.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Yamashita K, Kaneko M, Narukawa M. A significant anticancer drug approval lag between Japan and the United States still exists for minor cancers. Clin Pharmacol Ther. 2019;105:153–60.
Tsuji K, Tsutani K. If Japan is to become a front-runner in pharmaceutical development. Nature. 2008;32:851–2.
Ministry of Health, Labour and Welfare. Basic principles on Global Clinical Trials (Notification No.0928010 of Evaluating and Licensing Division, Pharmaceutical and Food Safety Bureau dated September 28, 2007) https://www.pmda.go.jp/files/000153265.pdf. Accessed June 3, 2020.
Kondo H, Shimada Y, Ozawa T. Promotion of Japan's participation in global clinical trials. Drug Discov Today. 2019;24:939–42.
Miyazaki K, Sato Y, Hanaoka H, Uyama Y. Current status and open issues concerning global clinical trials (GCTs) in Japan and East Asia. Clin Transl Sci. 2017;10:503–8.
Maeda H, Kurokawa T. Recent trends for drug lag in clinical development of oncology drugs in Japan: does the oncology drug lag still exist in Japan? Int J Clin Oncol. 2015;20:1072–80.
Onishi T, Tsukamoto K, Matsumaru N, Waki T. Industry perspective of pediatric drug development in the United States: involvement of the European Union countries. Therap Innov Regul Sci. 2018;52:49–56.
Pandolfini C, Bonati M. A literature review on off-label drug use in children. Eur J Pediatric. 2005;164:552–8.
Horen B, Montastruc JL, Lapeyre-Mestre M. Adverse drug reactions and off label drug use in paediatric outpatients. Br J Clin Pharmacol. 2002;54:665–70.
Ministry of Health, Labour and Welfare. Clinical Investigation of Medicinal Products in the Pediatric Population (ICH E11) (Notification No. 1334 of the Evaluating and Licensing Division, PMSB dated December 15, 2000) [in Japanese]. https://www.pmda.go.jp/files/000156072.pdf. Accessed June 3, 2020.
Saint RA. Regulatory aspects of drug development in children: change and resistance to change. Expert Rev Clin Pharmacol. 2010;3:593–5.
FDA Status Report to Congress: BPCA and PREA. Silver Spring, MD: FDA. July 2016.https://www.fda.gov/media/99184/download. Accessed June 3, 2020.
European Medicines Agency. 10-year report to the European Commission. EMA/231225/2015. https://ec.europa.eu/health/sites/health/files/files/paediatrics/2016_pc_report_2017/ema_10_year_report_for_consultation.pdf. Accessed June 3, 2020.
Baum VC, Bax R, Heon R, Yang Z, Sakiyama M. Pediatric drug regulation: international perspectives. Pediatric Anesthesia. 2019;29:572–82.
Nakamura H, Ono S. The Japanese perspective. In: Mulberg AE, Murphy D, Dunne J, Mathis LL, editors. Pediatric drug development: Concepts and applications. 2nd ed. Chichester, UK: Wiley; 2013, p. 170–176.
Ministry of Health, Labour and Welfare. Evaluation Committee on Unapproved or Off-Label Drugs with High Medical Needs (in Japanese).https://www.mhlw.go.jp/stf/shingi/other-iyaku_128701.html. Accessed June 3, 2020.
Ueyama E, Kaneko M, Narukawa M. Pediatric drug development in Japan: A comparison of the current situation and characteristics between Japan and Europe. Therap Innov Regul Sci. 2020;54:1152–58.
Pharmaceuticals and Medical Devices Agency. List of Approved New Products (in Japanese). https://www.pmda.go.jp/review-services/drug-reviews/review-information/p-drugs/0010.html. Accessed June 3, 2020.
ATC/DDD index 2020. WHO collaborating centre for drug statistics methodology. https://www.whocc.no/atcddd/indexdatabase/. Updated December 16, 2019. Accessed June 3, 2020.
Strickley RG. Pediatric oral formulations: an updated review of commercially available pediatric oral formulations since 2007. J Pharm Sci. 2019;108:1335–65.
European Medicines Agency. https://www.ema.europa.eu/en. Accessed June 3, 2020.
Hirai Y, Kinoshita H, Kusama M, Yasuda K, Sugiyama Y, Ono S. Delays in new drug applications in Japan and industrial R&D strategies. Clin Pharmacol Ther. 2010;87:212–8.
Ohwaki K, Nakabayashi T. Relationship between drug lag and factors associated with clinical trials in Japan. J Clin Pharm Ther. 2014;39:649–52.
Tanaka M, Nagata T. Characterization of clinical data packages using foreign data in new drug applications in Japan. Clin Pharmacol Ther. 2008;84:340–6.
Acknowledgements
We would like to thank Editage (www.editage.com) for English language editing.
Author information
Authors and Affiliations
Contributions
All authors were involved with drafting and revising this article.
Corresponding author
Ethics declarations
Conflict of interest
E.U. is an employee of Astellas Pharma Inc., Tokyo, Japan.
Rights and permissions
About this article
Cite this article
Ueyama, E., Kaneko, M. & Narukawa, M. Analysis of Pediatric Drug Approval Lag in Japan. Ther Innov Regul Sci 55, 336–345 (2021). https://doi.org/10.1007/s43441-020-00218-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s43441-020-00218-z